Thank you very much, Chair, and I do appreciate your being here, Chair.
I'm just going to take a moment very quickly to put a motion on notice today so that you're aware of it. I'll read it:
That, pursuant to Standing Order 108(2), the Standing Committee on Veterans Affairs undertake a study of no fewer than 8 meetings regarding the anti-malaria drug commonly known as Mefloquine, Mefliam, Lariam, and other brand names; that the study encompass the complete history of the drug distributed to members of the Canadian Armed Forces...from its first distribution to the present day; that the study consider all aspects of the use of Mefloquine and other anti-malaria drugs by the CAF, including, but not limited to its distribution, pricing, clinical testing, dosing, follow-up, side effects, a review of the latest research, a comparison with the experience of Canada's allies, and other related topics; and that the Committee report its findings to the House.
This committee, back in the day, did a brief study on this issue. We are far behind the rest of the world in acknowledging the damage this drug has done to our armed forces. I think it would be great to do a study. I will just put that on notice, if that's okay.